Snapshot · Boston Scientific Corporation (BSX)
Sector: Healthcare / Medical - Devices
Data as of 2026-09-01T00:35:21.175Z
Fundamentals check
- Market cap
- $71.8B
- P/E (TTM)
- 19.5
- Gross margin
- 71.2%
- Net margin
- 17.5%
- ROE
- 14.9%
- R&D / revenue
- 10.3%
- Dividend yield
- 0.0%
- FCF yield
- 5.0%
Summary
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
How it makes money
Revenue mix, latest fiscal year
- Cardiovascular66%
- MedSurg34%
Recent Events
- 2026-08-26T17:11:38.000Znegative
Stock Market Today, Aug. 26: Boston Scientific Shares Fall 5% on Cybersecurity Incident and Product Recall
事件可能与公司宣布的网络事件及全球运营受影响相关,恰逢市场对 BSX 短期股价波动,存在不确定性。
Source: fool.com
- 2026-08-20T00:00:00.000Znegative
Price move: BSX fell 5.1%
BSX 在这段行情中出现明显波动,恰逢异常的价格变动,但此处没有可关联到的具体新闻事件。
- 2026-08-03T00:00:00.000Zpositive
Price move: BSX rose 3.6%
BSX 在这段行情中出现明显波动,恰逢异常的价格变动,但此处没有可关联到的具体新闻事件。
- 2026-07-16T00:00:00.000Zpositive
Price move: BSX rose 3.7%
BSX 在这段行情中出现明显波动,恰逢异常的价格变动,但此处没有可关联到的具体新闻事件。
- 2026-07-02T00:00:00.000Zpositive
Price move: BSX rose 4.8%
BSX 在这段行情中出现明显波动,恰逢异常的价格变动,但此处没有可关联到的具体新闻事件。
- 2026-06-17T00:00:00.000Znegative
Price move: BSX fell 4.2%
BSX 在这段行情中出现明显波动,恰逢异常的价格变动,但此处没有可关联到的具体新闻事件。
Price & event timeline
Price & event timeline
Three months of price history with annotated events to help spot what may have driven a move.
筹码分布
资金流指标
以下为基于公开量价数据的技术指标估算,非真实主力资金流。
Analyst view
Wall Street ratings
Avg price target $65.14 from 22 analysts (last quarter)
Insider & Congress activity
聪明钱动向 · 近 90 天
内部人近 90 天整体偏买入,国会议员披露整体偏卖出。
Open-market trades only; grants and exercises excluded
- 2026-08-25BuyMorano Susan E(director)2,040 shares
- 2026-08-05BuyHabiger David C(director)2,100 shares
- 2026-08-04BuyHabiger David C(director)140 shares
- 2026-08-03BuyMahoney Michael F(director, officer: Chairman, President & CEO)186,240 shares
- 2026-08-03BuyHabiger David C(director)1,042 shares
US Congress trading disclosures
- 2026-06-04John Boozman (AR)Sale$1,001 - $15,000
Go deeper
订阅每日简报
每个交易日开盘/收盘后,中文市场简报直达邮箱。免费,随时退订。
本内容仅为信息整理,不构成任何投资建议。
Deep analysis
Deep analysis
Generate a full in-page analysis (business model, risks, scenarios). Not investment advice.